Gemlapodect
 | |
| Clinical data | |
|---|---|
| Other names | NOE-105; NOE105 |
| Routes of administration | Oral[1] |
| Drug class | Phosphodiesterase PDE10A inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H21N7O3 |
| Molar mass | 431.456 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gemlapodect (INN, USAN; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders.[1][2][3] It is taken orally.[1] The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons.[3] Gemlapodect was originated by Roche and is under development by Noema Pharma.[1][2] As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.[1][2]
See also
[edit]References
[edit]- 1 2 3 4 5 "Noema Pharma". AdisInsight. 18 September 2025. Retrieved 2 June 2026.
- 1 2 3 "Delving into the Latest Updates on Gemlapodect with Synapse". Synapse. 10 March 2026. Retrieved 2 June 2026.
- 1 2 Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |